| 引用本文: | 魏棒棒,曹怿玮,董春涛,顾浩,许飞飞,司鑫鑫.代谢组学在不同分子亚型乳腺癌中的研究进展[J].中国现代应用药学,2023,40(5):697-704. |
| WEI Bangbang,CAO Yiwei,DONG Chuntao,GU Hao,XU Feifei,SI Xinxin.Research Progress in Metabolomics in Different Molecular Subtypes of Breast Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(5):697-704. |
|
| 摘要: |
| 乳腺癌的治疗和预后受到分子分型影响，明确分子分型可让乳腺癌诊治更精准。代谢组学是继基因组学、转录组学和蛋白质组学后发展起来的一种组学技术，被广泛应用于肿瘤标志物的筛选和疾病诊断。近年来研究发现，乳腺癌各亚型之间具有代谢重编程的异质性，代谢组学所挖掘出的生物标志物为乳腺癌分子亚型的早期诊断、预后评估、药物靶点和机制研究以及毒理研究提供了高特异性、高灵敏度和高选择性的可视化指标。本文针对可作为乳腺癌各分子亚型的代谢标志物进行综述，以期为不同亚型乳腺癌的诊断和精准化治疗提供了一种新思路。 |
| 关键词: 乳腺癌 分子亚型 代谢组学 生物标志物 |
| DOI：10.13748/j.cnki.issn1007-7693.20221821 |
| 分类号:R969.1 |
| 基金项目:国家自然科学基金项目(81703557) |
|
| Research Progress in Metabolomics in Different Molecular Subtypes of Breast Cancer |
|
WEI Bangbang1, CAO Yiwei1, DONG Chuntao1, GU Hao1, XU Feifei2, SI Xinxin1
|
|
1.School of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China;2.School of Pharmacy, Nanjing Medical University, Nanjing 210000, China
|
| Abstract: |
| Treatment and prognosis of breast cancer are significantly affected by molecular subtyping, which can improve the precision of breast cancer diagnosis and treatment by clarifying molecular subtypes. Metabolomics is an omics technology developed following genomics, transcriptomics and proteomics, and it is widely used for the screening of tumor biomarkers and disease diagnosis. In recent years, studies had found heterogeneity in metabolic reprogramming among breast cancer subtypes. Biomarkers were uncovered by metabolomics that provided some highly specific, sensitive and selective visual indicators for the early diagnosis, prognostic assessment, drug target and mechanism studies, and toxicology studies of molecular subtypes of breast cancer. This paper reviews metabolic markers that can be used as various molecular subtypes of breast cancer and expects to provide a new idea for the diagnosis and precise treatment of different subtypes of breast cancer. |
| Key words: breast cancer molecular subtypes metabolomics biomarkers |
